Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar i disorder: A double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 76, Issue 3, 2015, Pages 284-292

  Calabrese, Joseph R ^a   Keck, Paul E ^b   Starace, Anj ^c   Lu, Kaifen ^d   Ruth, Ada ^e   Laszlovszky, Istva ^f   Nemeth, Gyorg ^a   Durgam, Sures ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LINDNER CENTER OF HOPE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e Prescott Medical Communications Group   (United States)

^f GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CARIPRAZINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT; PIPERAZINE DERIVATIVE;

ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; TREMOR; VOMITING; YOUNG MANIA RATING SCALE; ADOLESCENT; AKATHISIA, DRUG-INDUCED; BIPOLAR DISORDER; CLINICAL TRIAL; MIDDLE AGED; REMISSION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; BIPOLAR DISORDER; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLACEBOS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930532517     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14m09081     Document Type: Article

References (32)

1. Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry. 2010;71(12):1689-1695. doi:10.408/JCP.10m06347yel
2. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44. doi:10.1/bdi.12025
3. Harrison-Read PE. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors-A new analysis of data from the archives and implications for improved antimanic treatments. J Psychopharmacol. 2009;23(8):899-907. doi:10.17/02698108094349
4. Beaulieu JM, Tirotta E, Sotnikova TD, et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci. 2007;27(4):881-885. doi:10.1523/JNEUROSCI.5074-06.207
5. Cho DI, Zheng M, Kim KM. Current perspectives on the selective regulation of dopamine D and D receptors. Arch Pharm Res. 2010;33(10):1521-1538. doi:10.107/s1272-010-105-8
6. Leggio GM, Salomone S, Bucolo C, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013;719(1-3):25-33. doi:10.1016/j.ejphar.2013.07.02
7. Kiss B, Horti F, Bobok A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012;136(supplement 1):S190. doi:10.1016/S0920-964(12)7058-1
8. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial [published online ahead of print July 24, 2014]. Bipolar Disord. doi:10.1/bdi.1238
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
10. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382
12. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277. doi:10.176/api.ajp.201.101704
13. Guy W. The Clinical Global Impression Severity and Improvement Scales. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM). 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
14. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. doi:10.1093/schbul/13.2.261
15. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206.x
17. Guy W. The Abnormal Involuntary Movement Scale. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare publication (ADM). 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
18. Kenward MG, Molenberghs G, Thijs H. Pattern-mixture models with proper time dependence. Biometrika. 2003;90(1):53-71. doi:10.1093/biomet/90.1.53
19. Chen X, Luo X, Capizzi T. The application of enhanced parallel gatekeeping strategies. Stat Med. 2005;24(9):1385-1397. doi:10.102/sim.205
20. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9(7):811-818. doi:10.102/sim.478090710
21. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? Schizophr Res. 2005;79(2-3):231-238. doi:10.1016/j.schres.205.04.08
22. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):1680-1689. doi:10.102/hep.263
23. Yildiz A, Vieta E, Leucht S, et al. Efficacy of antimanic treatments: metaanalysis of randomized, controlled trials. Neuropsychopharmacology. 2011;36(2):375-389. doi:10.1038/np.2010.192
24. Beyer JL. An evidence-based medicine strategy for achieving remission in bipolar disorder. J Clin Psychiatry. 2008;69(suppl 3):31-37.
25. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry. 2008;65(4):386-394. doi:10.101/archpsyc.65.4.386
26. Gopal S, Steffens DC, Kramer ML, et al. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry. 2005;66(8):1016-1020. doi:10.408/JCP.v6n0809
27. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21(6):923-934. doi:10.185/0307905X46340
28. Ketter TA, Wang P, Nowakowska C, et al. Advances in the treatment of acute mania. In: Ketter TA, Calabrese JR, eds. Advances in Treatment of Bipolar Disorders: Review of Psychiatry Series. Washington, DC: American Psychiatric Association; 2005:11-56.
29. Tamayo JM, Zarate Jr. C.A., Vieta E, et al. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-Analysis. Int J Neuropsychopharmacol. 2010;13(6):813-832. doi:10.1017/S1461457091246
30. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11(5):453-473. doi:10.1/j.139-5618.209.0726.x
31. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. J Clin Psychiatry. 2007;68(6):917-923. doi:10.408/JCP.v68n0614
32. Maina G, Salvi V, Vitalucci A, et al. Prevalence and correlates of overweight in drug-nae patients with bipolar disorder. J Affect Disord. 2008;110(1-2):149-155. doi:10.1016/j.jad.207.12.23